Crossmark

Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence

Crossref DOI link: https://doi.org/10.1007/s00277-024-05910-w

Published Online: 2024-08-01

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xiaoli

Shangguan, Xiaohui

Wang, Hong

Wang, Qingyuan

Zhang, Yanming

Han, Bing

Liu, Rongrong

Zhang, Fengkui

Fu, Rong

Lin, Zenghua

Miao, Miao

Ma, Xiao

Lei, Meiqing

Wu, Depei

Liu, Limin
Funding

Funding for this research was provided by:

National Key Research and Development Program of China (2016YFC0902800, 2017YFA0104502, 2017ZX09304021)

Innovation Capability Development Project of Jiangsu Province (BM2015004)

Jiangsu Provincial Key Medical Center (YXZXA2016002)

Jiangsu Medical Outstanding Talents Project (JCRCA2016002)

Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and the Science Foundation of Suzhou (No.SKY2021040)
License Information

Text and Data Mining valid from 2024-08-01

Version of Record valid from 2024-08-01
More Information

Article History

Received: 14 December 2023

Accepted: 23 July 2024

First Online: 1 August 2024

Declarations

:

: The study was approved by institutional review boards and independent ethics committees at each center (leading ethics committee: ethics committee at the First Affiliated Hospital of Soochow University) and conducted in accordance with the Declaration of Helsinki. All patients or their guardians signed a written, informed consent at study inclusion.

: All authors review the manuscript and agree to its publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below